Premium
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF)
Author(s) -
McMurray John J.V.,
Anand Inder S.,
Diaz Rafael,
Maggioni Aldo P.,
O'Connor Christopher,
Pfeffer Marc A.,
Solomon Scott D.,
Tendera Michal,
Veldhuisen Dirk J.,
Albizem Moetaz,
Cheng Sunfa,
Scarlata Debra,
Swedberg Karl,
Young James B.
Publication year - 2013
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1093/eurjhf/hfs204
Subject(s) - medicine , heart failure , darbepoetin alfa , interquartile range , clinical endpoint , clinical trial , randomization , cardiology , randomized controlled trial , anemia
Aims This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. Methods and results Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED‐HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED‐HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m 2 ). Patients in RED‐HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED‐HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study‐specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L. Conclusion The anaemic patients enrolled in RED‐HF were older, moderately to markedly symptomatic, and had extensive co‐morbidity.